More Vapes May Reach Shelves Before FDA Review — Even Agency Staff Were Caught Off Guard

The Food and Drug Administration (FDA) has quietly issued new guidance permitting certain nicotine products to remain on sale while undergoing scientific review, a move that blindsided senior agency staff who reportedly learned of the decision only the night before it was made public. This policy shift represents a significant departure from the FDA's previous stance of blocking flavored nicotine products unless companies could demonstrate they benefited adult smokers without attracting children. The decision comes as flavored disposable vapes are already deeply embedded in the market, with Chinese-made products accounting for approximately 80% of U.S. vape sales. The policy change carries major financial implications for the tobacco industry, which is under pressure to replace lost cigarette revenue, and may advantage larger tobacco companies with resources to navigate lengthy reviews over smaller vaping businesses. The move has intensified political pressure, with President Donald Trump having publicly promised to "save" the vaping industry, and tobacco giants like Reynolds American and Altria having invested millions in political groups aligned with Republican priorities. The decision has sparked broader concerns about whether public institutions can effectively regulate industries that are moving faster than the regulatory systems designed to control them, particularly regarding products marketed to younger consumers.

(Source：Finance Monthly)